U.S. markets closed
  • S&P 500

    3,655.04
    -38.19 (-1.03%)
     
  • Dow 30

    29,260.81
    -329.60 (-1.11%)
     
  • Nasdaq

    10,802.92
    -65.00 (-0.60%)
     
  • Russell 2000

    1,655.88
    -23.71 (-1.41%)
     
  • Crude Oil

    76.34
    -0.37 (-0.48%)
     
  • Gold

    1,629.30
    -4.10 (-0.25%)
     
  • Silver

    18.34
    -0.14 (-0.76%)
     
  • EUR/USD

    0.9611
    -0.0077 (-0.80%)
     
  • 10-Yr Bond

    3.8780
    +0.1810 (+4.90%)
     
  • GBP/USD

    1.0683
    -0.0173 (-1.60%)
     
  • USD/JPY

    144.6910
    +1.3710 (+0.96%)
     
  • BTC-USD

    19,110.92
    +319.48 (+1.70%)
     
  • CMC Crypto 200

    438.96
    +5.86 (+1.35%)
     
  • FTSE 100

    7,020.95
    +2.35 (+0.03%)
     
  • Nikkei 225

    26,431.55
    -722.28 (-2.66%)
     

Delcath Stock Moves Higher After Hepzato Achieves ORR Of 29.2% Beating Prespecified Threshold In Eye Cancer Study

·1 min read
  • Delcath Systems Inc (NASDAQ: DCTH) has announced top-line preliminary results from the Phase 3 FOCUS trial of Hepzato Kit (melphalan hydrochloride for injection/hepatic delivery system) in patients with liver dominant metastatic ocular melanoma.

  • Based on the preliminary analysis of 87% of enrolled patients, the assessed overall response rate (ORR) of 29.2% in the Intent to Treat population exceeded the predefined success criteria (21.0%) for the primary ORR endpoint.

  • Evaluable patients in the HEPZATO arm showed ORR of 32.9% versus 13.8% for the Best Alternative Care (BAC) arm.

  • The Median Progression-Free Survival for the BAC arm was 9.0 months versus 3.1 months.

  • A Disease Control Rate of 70.9% was observed versus 37.9% for patients in the BAC arm.

  • Duration of Response and Overall Survival is not yet evaluable.

  • In the HEPZATO safety population of 94 patients, 38 patients (40.4%) experienced a treatment-emergent serious adverse event, most commonly were thrombocytopenia (14.9% of patients), neutropenia (10.6% of patients), and leukopenia (4.2% of patients), which were well-manageable.

  • 5% of patients experienced treatment-emergent serious cardiac adverse events.

  • The preliminary results are based on a data cut on March 12 and include 79 treated HEPZATO patients.

  • Price Action: DCTH shares are trading 16.7% higher at $19 in premarket on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.